Sponsors (7)
The bill increases clarity and consistent consumer protections by defining direct-to-consumer advertising in law, but does so at the cost of added compliance burdens for industry, potential limits on online marketing channels consumers use, and additional FDA resource needs.
Patients with chronic conditions gain clearer protections because the bill creates a statutory definition of direct-to-consumer (DTC) advertising, making it more transparent which communications are covered by regulation.
All consumers—especially patients with chronic conditions—receive consistent legal treatment because the definition is applied uniformly to all approved/licensed drugs, ensuring equal protections regardless of a drug's approval date.
Drug manufacturers and sponsors will likely incur new compliance costs and operational burdens to ensure advertising aligns with the statutory definition, which could raise administrative costs for hospitals and health systems that interact with or rely on manufacturer communications.
Patients (notably those with chronic conditions) may have reduced access to information if the FDA uses the definition to impose tighter restrictions on online and social media marketing channels where many consumers learn about therapies.
The FDA will need to allocate staff and resources to implement and enforce the new statutory provision, potentially diverting agency resources or requiring additional appropriations that affect public agencies and stakeholders.
Based on analysis of 2 sections of legislative text.
Defines direct-to-consumer advertising for prescription drugs and brings such ads under the FD&C Act’s regulatory coverage, effective 30 days after enactment.
Adds a new provision to the Federal Food, Drug, and Cosmetic Act that defines “direct-to-consumer advertising” for prescription drugs and brings such advertising under the Act’s coverage. The definition covers promotional communications aimed at consumers through television, radio, print, digital platforms, and social media for drugs approved or licensed by federal law. The change takes effect 30 days after the law is enacted and applies to all covered drugs regardless of when they were approved or licensed.
Introduced June 12, 2025 by Bernard Sanders · Last progress June 12, 2025